For most stroke patients, NAC treatment didn't significantly change most blood markers related to oxidative stress compared to standard treatment alone.
Scientific Claim
N-acetylcysteine administration did not significantly improve most oxidative stress biomarkers (catalase, paraoxonase, TAC, MDA, neopterin) in the overall ischemic stroke patient group when compared to standard treatment alone.
Original Statement
“TACIntervention/before = 3474 ± 257.48 versus TACIntervention/after = 3579.50 ± 210.16 (P = 0.75), TOSIntervention/before = 113.28 ± 12.57 versus TOSIntervention/after = 79.70 ± 8.25 (P = 0.02), MDAIntervention/before = 10.14 ± 1.75 versus MDAIntervention/after = 8.30 ± 1.24 (P = 0.42), CatalaseIntervention/before = 4.44 ± 0.68 versus CatalaseIntervention/after = 6.19 ± 0.94 (P = 0.10), ParaoxonaseIntervention/before = 22.03 ± 1.43 versus ParaoxonaseIntervention/after = 22.61 ± 1.35 (P = 0.55), and NeopterinIntervention/before = 1.81 ± 0.36 versus NeopterinIntervention/after = 1.54 ± 0.27 (P = 0.13).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The RCT design supports the conclusion that most biomarkers did not show significant changes. The verb 'did not significantly improve' is appropriate for this finding.
Evidence from Studies
Supporting (1)
Investigation of the effect of N-acetylcysteine on serum levels of oxidative inflammatory biomarkers in patients with stroke